Omkar Speciality Chemicals Exits CIRP, Posts Zero Revenue, Slashes Debt

Omkar Speciality Chemicals Limited has officially transitioned out of the Corporate Insolvency Resolution Process (CIRP) following the National Company Law Tribunal's (NCLT) approval of its resolution plan on July 31, 2025. The company has since released its unaudited financial results for the first three quarters of the fiscal year 2025-26.

Reader Takeaway: Debt significantly reduced post-resolution, but zero revenue and losses continue.

What Just Happened

The company has announced its unaudited financial results for the quarters ending June 30, 2025, September 30, 2025, and December 31, 2025. These results reflect the period post the NCLT approval of the resolution plan and the transition to a new management structure. Mr. Dipak Kumar Shaw has been appointed as the Chief Executive Officer (CEO), and Mr. Ruhini Kumar Chakraborty as an Independent Director. R. R. Tibrewala & Co. has been appointed as the Statutory Auditor for FY 2025-26.

Why This Matters

This disclosure marks a critical turning point for Omkar Speciality Chemicals as it moves past its insolvency proceedings. The substantial reduction in debt is a key positive outcome of the approved resolution plan. However, the continued absence of operational revenue and persistent net losses highlight the significant challenges ahead in reviving the business. Investors will be closely watching the company's ability to restart its core operations and achieve profitability under the new leadership.

The Backstory

Omkar Speciality Chemicals underwent the Corporate Insolvency Resolution Process (CIRP) due to its financial distress. The NCLT's approval of the resolution plan on July 31, 2025, paved the way for its exit from CIRP and the restructuring of its balance sheet.

What Changes Now

With the CIRP concluded, the company is under new management, including a newly appointed CEO and Independent Director. A new bank account has been opened with ICICI Bank to manage daily operations. The focus shifts from insolvency resolution to business revival and operational execution.

Risks to Watch

The primary risks include the company's inability to generate operational revenue, continued net losses, and the successful execution of the resolution plan's strategic initiatives for capital expenditure and working capital. The auditor's qualified conclusion, particularly regarding the going concern basis despite negative net worth, also warrants attention.

Peer Comparison

Given the company's focus on specialty chemicals and its recent exit from insolvency, direct peer comparisons are challenging without specific operational data. However, the specialty chemical sector in India is generally competitive and requires continuous investment in R&D and manufacturing efficiency.

Context Metrics

• Total Resolution Amount: ₹26.65 crore
• Funds Infused by Applicant (Up to Dec 2025): ₹15.08 crore
• Borrowings (Before Plan - Mar 31, 2025): ₹382.35 crore
• Borrowings (Post-Plan - Sep 30, 2025): ₹16.79 crore
• Revenue from Operations (FY 2025-26 Q1-Q3): ₹0 crore
• Net Profit/(Loss) (FY 2025-26 Q1-Q3): ₹-0.41 crore, ₹-0.52 crore, ₹-0.33 crore respectively.

What to Track Next

Investors should monitor the resumption of revenue from operations, the progress in deploying capital for growth and working capital, and the company's path towards achieving profitability. The successful turnaround of the business under the new management team will be the key factor to track.